-
-
Cyclooxygenase 2 (COX 2) inhibitors may not be as safe as previously thought. These agents have a considerable risk of adverse gastrointestinal events. The concurrent use of ulcer-healing drugs appears to decrease this risk.
-
The strong correlation between reduction of aura symptoms and migraine attacks stresses the potential role of aura-like events and possibly cortical spreading depression as a trigger for trigeminal vascular activation, and subsequently the development of migraine headaches.
-
A very small group of patients consume a significant portion of outpatient primary care physician time.
-
Infliximab, an antibody against tumor necrosis factor, is effective in ulcerative colitis.
-
A new drug has been approved for the treatment of children with below average height who are resistant to growth hormone. Mecasermin is a human insulin-like growth factor-1 (IGF-1) that is produced by recombinant DNA technology. This protein is marketed by Tercica, Incorporated as Increlex.
-
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions
-
This warning jumps off the page from the first-ever National Report Card on the State of Emergency Medicine, just released by the Dallas-based American College of Emergency Physicians (ACEP). The report covered all 50 states and the District of Columbia.
-
-
If youre in the market for a CPOE, its important to play with a number of systems before making your choice to determine which is most user friendly and which is the best fit for your ED, advises Brian F. Keaton, MD, FACEP, attending physician/emergency medicine informatics director at Summa Health System, Akron, OH, and president-elect of the American College of Emergency Physicians (ACEP).
